Paradigm Capital Management Inc Opti Nose, Inc. Transaction History

Paradigm Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$1.55 - $3.1 $1.09 Million - $2.18 Million	-703,321 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$2.35 - $3.16 $3.14 Million - $4.22 Million	-1,335,000 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$2.91 - $3.83 $3.37 Million - $4.44 Million	-1,159,000 Reduced 46.47%	1,335,000 $4.15 Million
Q1 2021 May 05, 2021	SELL	$3.47 - $4.75 $17,350 - $23,750	-5,000 Reduced 0.2%	2,494,000 $9.2 Million
Q4 2020 Jan 20, 2021	BUY	$3.2 - $4.98 $604,800 - $941,220	189,000 Added 8.18%	2,499,000 $10.3 Million
Q3 2020 Oct 20, 2020	BUY	$3.69 - $7.09 $5.78 Million - $11.1 Million	1,567,400 Added 211.07%	2,310,000 $9.01 Million
Q2 2020 Aug 03, 2020	BUY	$3.58 - $7.44 $2.3 Million - $4.77 Million	641,600 Added 635.25%	742,600 $5.53 Million
Q4 2019 Feb 05, 2020	BUY	$6.27 - $11.41 $313,500 - $570,500	50,000 Added 98.04%	101,000 $931,000
Q3 2019 Nov 07, 2019	BUY	$4.75 - $8.38 $190,000 - $335,200	40,000 Added 363.64%	51,000 $357,000
Q2 2019 Aug 08, 2019	BUY	$6.4 - $10.94 $70,400 - $120,340	11,000 New	11,000 $78,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $42.5M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of Paradigm Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Paradigm Capital Management Inc with notifications on news.